going long, page-8

Article from a major NY online publication ..... refer below


A Diamond in the Rough

By GS Early

We've all been watching the dramatic gyrations of the stock markets
around the world as the US financial and mortgage sectors try to sort
out how hard to land in the official end to the US housing bubble.

The market has been on a manic upswing Friday, and both the Dow Jones
Industrial Average and Nasdaq Composite are making it a much better
weekend than if you headed out of town yesterday. And it wasn't until
late in this depressive trend that many of my nano stocks started to
get hit. But some stocks in my Pioneers Portfolio have now become
short targets and are paying a price for no particular reason.

For example, one well-run exciting company I follow is trading at new
52-week lows and, even in today's uptrended market, is down two
cents. This is a company with ZERO debt on its books and enough
operating capital to get through the next 18 months without another
deal coming through the door. It's also a company whose largest
shareholder is pharma giant Pfizer, which is committed to pouring
tens of millions of dollars into the company in coming months and
years.

And just this week, as its stock continued to plummet, it released
news that it completed recruitment for its pancreatic cancer study in
Europe in Phase IIa trials. That's some encouraging news in and of
itself.

But here's what the preliminary studies have shown:

Eight weeks follow-up data available on the first 10 patients treated
shows 90% of these patients have had either stabilization or
reduction in size of their primary tumor and none of these patients
experienced product related significant adverse events.

This is some seriously good news. Most drug trials wash out in Phase
II when efficacy is put through its paces on humans.

These trials will be on a smaller group than the Phase III trials,
but for a virtually untreatable cancer, any improvement from waiting
for the inevitable is headway. It's presenting significant safety and
efficacy results in this small sample, which portends a similar trend
in a larger sample.

Even if half the patients demonstrated stasis or improvement, it
would be a compelling story. Final results will be announced in
December or January.

The market isn't smarter than you are; there are just some people
having fun out there right now. This company has a lot more liquidity
in the US market now with its recent secondary institutional
offerings, and there's a lot of momentum players jumping in just to
make some quick money.

But when this thing turns, it's going to be pretty exciting.So I've
created a report for Nanotech Investor News subscribers covering this
exciting little company and it's state of the art drug delivery
system… plus four other pioneering companies in my latest report
Nanotech Pioneers: Small Stocks With Huge Profit-Potential."
AFTER 2 hours of dd I found out it...it's PSDV
http://tinyurl.com/33657u
IT'S TRUE, PFE IS IN
[In July 2007, the Company raised approximately US$18.4m (A$21.4m) of
net proceeds from share placements including a US$6.5m (A$7.5m)
investment by Pfizer raising their total investment in the Company to
US$11.5m (A$13.7m). The Company currently expects that it has
sufficient cash to fund operations for more than 12 months.


Worldwide Collaborative Research and License Agreement with Pfizer
pSivida signed an exclusive worldwide Collaborative Research and
License Agreement with Pfizer Inc. for pSivida's controlled drug
delivery technologies in ophthalmic applications in April 2007. Under
the terms of the agreement, pSivida will receive up to approximately
US$155m (A$182m) in development and sales related milestones. Pfizer
made an initial investment of US$5.0m (A$6.1m) in ordinary shares of
pSivida and subsequently made an additional US$6.5m (A$7.5M)
investment in American Depository Shares (ADSs) in July 2007. The two
companies will work together on a joint research program aimed at
developing ophthalmic products using pSivida's sustained drug
delivery technology. In addition to the milestone payments described
above, Pfizer will fund the cost of the joint research program. This
license agreement followed the completion of 12 months of evaluation
of pSivida's drug delivery technologies by Pfizer. pSivida is free to
license its Medidur(TM) drug delivery technology for non-ophthalmic
applications.
pSivida Redeems all Convertible Notes
All convertible notes have been redeemed enabling the Company to
move forward with a simpler capital structure. ]
that's all folks!